ARTICLE | Company News
Sonus, Abbott deal
April 10, 2000 7:00 AM UTC
ABT will return to SNUS U.S. marketing rights for SNUS's EchoGen perflenapent injectable ultrasound contrast agent at no cost to SNUS, following renegotiation of the rights under a modified license ag...